Applicant, as named in the Orange Book

Rigel Pharms

Next listed expiry: Tavalisse on 27 Jul 2032. 4 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Tavalisse NDA 209299 · 2 strengths fostamatinib disodium	fostamatinib disodium	27 Jul 2032 patent	patent
Veppanu NDA 219835 · 2 strengths vepdegestrant	vepdegestrant	30 Jan 2038 patent	patent
Rezlidhia NDA 215814 olutasidenib	olutasidenib	12 Nov 2039 patent	patent
Gavreto NDA 213721 pralsetinib	pralsetinib	19 Apr 2043 patent	patent

Tavalisse · First generic approved · ANDA 217329, Annora PharmaApproved 17 Jun 2026Detected 25 Oct 2026
Tavalisse · Generic approved · ANDA 217329, Annora PharmaApproved 17 Jun 2026Detected 25 Oct 2026